Indirect antitumor effects of mammalian target of rapamycin inhibitors against Kaposi sarcoma in transplant patients.
Barozzi
Patrizia
P
Riva
Giovanni
G
Vallerini
Daniela
D
Bosco
Raffaella
R
Quadrelli
Chiara
C
Zanetti
Eleonora
E
Potenza
Leonardo
L
Forghieri
Fabio
F
Torelli
Giuseppe
G
Luppi
Mario
M
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D005871:Castleman Disease / Q000209:etiology / Q000276:immunology; D019288:Herpesvirus 8, Human / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology; D054685:Lymphoma, Primary Effusion / Q000209:etiology / Q000276:immunology; D011494:Protein Kinases / Q000187:drug effects*; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000821:virology; D020123:Sirolimus / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D058570:TOR Serine-Threonine Kinases; D014181:Transplantation Immunology
D000903:Antibiotics, Antineoplastic; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus